The availability of promising TRAF2-targeting agents, such as liquidambaric acid [61] and anti-TNFR2 antibodies currently under clinical evaluation (NCT04752826) [62], strengthens the rationale for TRAF2 as a potential mediator in TFAM-low GBM. This evidence concerns the gene TFAM and glioblastoma.